Dickon drug industry No money dividend push high send 10 ext. 15

Every reporter Wang Yandan today, Dickon Pharmaceutical (600466, closing price of 14.41 Yuan) released the 2010 Annual report. Although the cumulative profit for shareholders at the end of last year was negative, the company is still intending to increase by 15 shares per 10 shares. High sent to "return shareholders" bulletin shows that the Dickon pharmaceutical industry in 2010 to achieve business income of 322 million yuan, an increase of 2.48%, net profit of 30.9665 million yuan, increased by 110.8% ; The net profit is only 15.4228 million yuan after deducting the non-recurrent income, the basic earnings per share is 0.1763 yuan and the net assets yield is 6.16%. Although the operating performance is not brilliant, Dickon pharmaceutical industry has put forward enough to make the market stunning bonus plans. The company said in its annual report that due to the cumulative end of 2010 for shareholders to allocate profits of 81.106 million yuan, the company's profits will be all used to make up the previous losses, so can not make profit distribution. However, "comprehensive consideration of the long-term development of the company, the return of shareholders and other factors", the company intends to use Provident Fund 10 shares to increase 15 shares. While many of the listed companies have offered high transfers this year, it is not much of a generous move to increase equity. According to wind statistics, as of March 2, only the golden channeling (300091, closing price of 55.20 Yuan), Juloka (300099, closing price of 111.80 yuan), Sino-Swiss Thinking (300078, Closing price of 83.15 yuan) 3 companies proposed the increase in capital accumulation of 10 to 15, and these three companies are listed last year gem new shares. In addition, the Wuzhou Pearl (600873, closing price of 41.36 Yuan) proposed 10 to 16.86, is currently the largest shares. From the level two market performance, Dickon pharmaceutical industry This generous increase in equity seems to have a financial foresight. From January 27 onwards, the Dickon pharmaceutical industry launched a fierce offensive, a short period of one months has been nearly 50%. The annual report on new shares shows that the pharmaceutical business of the Dickon pharmaceutical industry has grown steadily in 2010. The Board pointed out that the key products Ansfield for three consecutive years to maintain sales growth, market share continues to improve, other products Dragon seven stomach tablets, Tongqiao rhinitis granules, Kidney Shu granules, Ann can be sold also maintained a relatively fast growth. Medical devices, after several years of development, its Chengdu di Kang Zhongke Biomedical Materials Co., Ltd. has developed a series of biodegradable biomedical materials and its series of medical equipment, and has a high market share. 2011 The company will actively build and build a comprehensive coverage of the marketing team, increase market development efforts, highlighting the core products, and strive to improve the share of existing products, while introducing and developing 1~2 new drugs, further improve the viability and competitiveness of enterprises. Interestingly, it is clear from the annual report that, in the face of last year's a-share market IPO boom, the company showed strong interest, and good luck, has been checked for up to 22 new shares. Among them, the most checked is China's electricity in the West (601179, closing price of 8.35 yuan), a total of 7000 shares. Next is the waterfront shares (601678, closing price of 26.86 yuan), 2000 shares. The rest of the SME board, gem new shares are basically only 500 shares. The company said that last year's sale of new shares to obtain investment income of 121,400 yuan.